venetoclax
roche,abbvie
['mds', 'venetoclax']
congress #eha2023 | alexandre bazinet presents frequency, characteristics &amp; natural history of ep #mds and outcomes of venetoclax-based treatment. ep mds had more frequent complex cytogenetics, tp53 mutations, higher risk ipss-r &amp; shorter os vs non-ep mds. #mdssm 
Lifting levels of knowledge in myelodysplastic syndromes (#MDS). A global online platform providing latest treatment options and medical information. #mdssm